Novo Nordisk Investigational Site
Tokyo, 1000005, Japan
NCT Number: NCT00154414
This trial is conducted in Japan. The aim of this research trial is to evaluate the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in Japanese subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group.
Looking for future studies?
Notify Me20 year–74 year
All sexes
Interventional
Phase 2
Tokyo, 1000005, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: after 14 weeks treatment
Novo Nordisk A/S
Industry
Effect of Liraglutide on Glycaemic Control in Japanese Subjects With Type 2 Diabetes.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03899883
Diabetes, Diabetes Complications
Aurora, Colorado, United States
View Trial DetailsNCT04286555
Cardiovascular Diseases, Diabetes
Baltimore, Maryland, United States
View Trial DetailsNCT07524166
Diabete Mellitus, Diabetes
Jiaxing, Zhejiang, China
View Trial DetailsNCT06094920
Albuminuria, CKD
Almelo, Overijssel, Netherlands
View Trial Details